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Abstract Twelve cases of unbearable pruritus several days
after withdrawal of (levo)cetirizine were reported to the
Netherlands Pharmacovigilance Centre Lareb. Eleven reports
concerned women and one report concerned a man, aged
19–58 years. These patients had been using these antihis-
tamines continuously for months or years. They had tried to
stop using antihistamines on several occasions but felt unable
to withdraw the drug because of the unbearable maddening
itch. Finally, slowly tapering the drug or using a short course
of corticosteroids helped to withdraw (levo)cetirizine. The
Naranjo assessment score ranged from two to four for all the
cases, indicating a possible relationship.
Key Points
(Levo)cetirizine is widely used in the treatment of
allergic rhinitis and is tolerated well.
However, generalised pruritus after withdrawal can
occur, making patients feel unable to stop using the
antihistamine.
Gradually reducing the dose of the (levo)cetirizine or
a short course of corticosteroids might help in
withdrawing the antihistamine.
Introduction
Allergic rhinitis is an inflammatory immunoglobulin
E-mediated disease with symptoms of sneezing, nasal
pruritus, nasal congestion and nasal discharge. Triggering
allergens include seasonal pollens and moulds, as well as
dust mites and pets. Allergic rhinitis can be seasonal or
year round, with symptoms being intermittent or persistent
[1]. Sensitisation to inhaled allergens begins during the first
year of life. The prevalence of allergic rhinitis peaks in the
second to fourth decades of life and then gradually
diminishes [2]. Allergic rhinitis is a common disease, with
a prevalence estimated between 10 and 30% of the popu-
lation [3]. Treatment options include H1-antihistamines,
intranasal glucocorticoids, leukotriene-receptor antagonists
and allergen immunotherapy [2]. Oral antihistamines have
been in use since 1940. These agents are effective for the
relief of symptoms including rhinorrhoea, sneezing, itch-
ing, nasal blockage as well as associated ocular complaints.
Oral antihistamines can be broadly categorised as first- or
second-generation antihistamines. The first-generation
antihistamines have side effects such as sedation and
mucosal dryness, which limit their use. Second-generation
antihistamines are highly selective for the H1 receptor and
have limited penetration of the central nervous system.
Cetirizine and levocetirizine belong to the second-genera-
tion antihistamines. Levocetirizine is the active R-enan-
tiomer of cetirizine. The advantages of treatment with oral
antihistamines include a rapid onset of action, once-daily
dosing, maintenance of effectiveness with regular use and
the availability of some drugs without a prescription.
Maximum benefit is seen with continuous use, but in
patients with intermittent symptoms use on an as-needed
basis can provide significant symptom relief [1].
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In the period from October 1989 to June 2016, the
Netherlands Pharmacovigilance Centre Lareb received 12
reports of unbearable pruritus after withdrawal of cetirizine
or levocetirizine. Four reports were reported by healthcare
professionals and eight reports were reported by con-
sumers. Striking in these reports is the occurrence of a
maddening generalised itch after withdrawal of the anti-
histamine, which is reported to be different to the com-
plaints that the antihistamines were used for in the first
place.
Case Reports
Lareb received 12 reports of generalised pruritus after
withdrawal of (levo)cetirizine (Table 1). The patients
described pruritus without any other symptoms such as
rashes or urticaria. The reports concerned 11 women
and one man with a median age of 39 years (range
19–58 years). The pruritus occurred 1–3 days after
withdrawal of long-term use of (levo)cetirizine. The
patients had been using (levo)cetirizine continuously for
months or years. Nine patients reported that they tried
to stop using (levo)cetirizine several times but were not
able to withdraw the drug because of the unbearable
itch. One patient reported that a gradual reduction in
dose helped and that after several weeks, the itching
slowly receded and eventually disappeared. Another
patient used a short course of corticosteroids. Five
patients reported the use of concomitant medication.
The concomitant medication was started years before
the onset of the pruritus (1–13 years). The following
case report (case 11 in Table 1), with a report date of
24 February, 2016, is representative of the cases
reported to Lareb.
A 20-year-old woman had been using levocetirizine for
hay fever for 2 years. Twenty-six hours after withdrawal
she experienced pruritus. It started as a burning itch
across the hands. The pruritus aggravated gradually across
her head and was generalised after 2 days. It was
unbearable, she could not sleep and was unable to go to
work. In the past, she had tried to stop using levoceti-
rizine several times, but every time there was more than
24 h between the intake of tablets, she would experience
pruritus. The longer the period between the intake
between two tablets, the worse the pruritus became. When
she took levocetirizine, the pruritus would disappear
within 30 min. Therefore, she felt unable to withdraw
levocetirizine. Ultimately, she was treated with pred-
nisolone for 1 week and is recovering 3 weeks after
withdrawal. The Naranjo causality score for this case was
three.
Discussion
Pruritus is a common symptom that is experienced by all
humans at some point in life. It occurs in a diverse range of
skin diseases and may affect the skin, mucous membranes
and cornea. The frequent occurrence of pruritus is sup-
ported by the results of epidemiological studies that found
the prevalence of pruritus in the general population was
approximately 8% [4].
Unbearable itch after withdrawal of antihistamines is not
a common phenomenon. A PubMed search revealed no
published reports of this association. However, there has
been extensive discussion about the occurrence of pruritus
after withdrawal of (levo)cetirizine on several patient for-
ums and blogs [5, 6].
Antihistamines are used for the treatment of pruritus and
therefore one would expect that withdrawal of antihis-
tamines leads to the same symptoms for what the antihis-
tamines were described. However, the patients in the cases
reported to the Netherlands Pharmacovigilance Centre
Lareb describe the generalised unbearable itch as a com-
pletely different itch for which (levo)cetirizine was
described. In the majority of cases, the indication for use
was hay fever.
Many internal diseases may present with itching symp-
toms. Pruritus is a frequent manifestation in patients with
liver diseases and intra- or post-hepatic cholestasis, a sign
of chronic renal insufficiency and a number of haemato-
logical diseases such as polycythaemia vera [7]. There is
no indication in the reported cases that patients experienced
any of these underlying diseases because there are no other
reactions reported besides pruritus and no concomitant
medication that would suggest the presence of such ill-
nesses. Unfortunately, no laboratory values were provided
in the reports to exclude underlying diseases, but there
were four reports that were medically confirmed and these
healthcare providers did not mention any other causes for
the pruritus.
Although (levo)cetirizine has been reported to cause
nephritis or hepatotoxicity [8, 9], this is an unlikely cause
of the pruritus in these cases as the reaction only started
after withdrawal of the drug and there were a number of
patients with ‘positive re-challenges’. Pruritus can be a side
effect of a variety of drugs, such as morphine, opioids,
angiotensin converting enzyme inhibitors, analgesics,
vitamin A, contrast media, gold, chloroquine and sulpho-
namides [10]. However, all the concomitant medications
that were reported had already been used years prior to the
reaction and the time relation strongly links the pruritus to
the withdrawal of (levo)cetirizine.
The Naranjo causality score ranged from two to four for
all the cases. This is a relatively low score. However, the
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Naranjo causality score is not really suited for withdrawal
reactions [11].
How long-term treatment with (levo)cetirizine may
cause this withdrawal reaction is not known. H1 receptors
mediate allergy in peripheral tissues and histaminergic
neurotransmission in the central nervous system. The H1
receptor (H1R) gene is upregulated in patients with polli-
nosis. Its expression level is highly correlated with allergic
symptom severity. Antihistamines are widely used as
allergy treatments because they inhibit histamine signalling
by blocking H1R or suppressing H1R signalling as inverse
agonists [12]. Long-term treatment with antihistamines can
decrease H1R gene expression to the basal level [13]. It is
hypothesised that after stopping long-term treatment, H1R
blockade disappears relatively fast (the half-life of
(levo)cetirizine is 6–10 h). In the presence of histamine,
this can lead to occupancy of the H1R and because the
number of H1R was down-regulated owing to long-term
treatment, a relatively high percentage of H1R will be
occupied with histamine, possibly resulting in itch. Short-
term use will probably not lead to these symptoms because
down-regulation of H1R has not been achieved in that
time. It is remarkable that the patients reported at Lareb
only experienced itch and no other symptoms induced by
occupancy of the H1 receptor.
(Levo)cetirizine is a commonly prescribed drug in the
Netherlands. Around 430,000 patients each year are pre-
scribed (levo)cetirizine [14]. Levocetirizine and cetirizine
are the only antihistamines in the Lareb database of which
there are reports about this withdrawal reaction. There are
no reports of unbearable itch after withdrawal of other
antihistamines.
Conclusion
Based on the cases reported to the Netherlands Pharma-
covigilance Centre Lareb, we suggest a causal relation
between withdrawal of (levo)cetirizine and the occurrence
of unbearable pruritus. The Naranjo assessment score
ranged from two to four for all the cases, indicating a
possible relationship. Healthcare professionals should be
aware that in some patients this reaction can occur. Grad-
ually reducing the dose of the (levo)cetirizine or a short
course of corticosteroids might help in withdrawing the
antihistamine.
Compliance with Ethical Standards
Funding No financial support was received for the conduct of this
study or preparation of this article.
Conflict of interest Corine Ekhart, Petra van der Horst and Florence
van Hunsel declare that they have no conflicts of interest.
Consent for publication Written informed consent was obtained
from the patient in the detailed case description (case 11 in Table 1)
for the publication of the case report. A copy of the consent may be
requested for review from the corresponding author.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice
guideline: allergic rhinitis. Otolaryngol Head Neck Surg.
2015;152(1 Suppl.):S1–43.
2. Wheatley LM, Togias A. Clinical practice: allergic rhinitis.
N Engl J Med. 2015;372(5):456–63.
3. Wang XY, Lim-Jurado M, Prepageran N, et al. Treatment of
allergic rhinitis and urticaria: a review of the newest antihis-
tamine drug bilastine. Ther Clin Risk Manag. 2016;12:585–97.
4. Dalgard F, Svensson A, Holm JO, Sundby J. Self-reported skin
morbidity among adults: associations with quality of life and
general health in a Norwegian survey. J Investig Dermatol Symp
Proc. 2004;9(2):120–5.
5. The People’s Pharmacy. Cetirizine (Zyrtec) withdrawal and
unbearable itching. Available from: http://www.
peoplespharmacy.com/2013/05/06/cetirizine-zyrtec-withdrawal-
unbearable-itching/. Accessed 21 Nov 2016.
6. MedHelp. Addicted to Zyrtec? Available from: http://www.
medhelp.org/posts/Allergy/addicted-to-zyrtec/show/600862.
Accessed 21 Nov 2016.
7. Peharda V, Gruber F, Kasˇtelan M, et al. Pruritus an important
symptom of internal diseases. Acta dermatovenerologica Alpina
Panonica et Adriatica. 2000;9(3):92–104.
8. Raghavendran R, Shipman AR, Langman G, et al. Acute inter-
stitial nephritis secondary to long-term use of cetirizine for the
treatment of urticaria pigmentosa. Clin Exp Dermatol.
2013;38(1):100–1.
9. Ekiz F, Yu¨ksel I, Ekiz O, et al. Levocetirizine induced hepato-
toxicity in a patient with chronic urticaria. Ann Hepatol.
2011;10(2):237–8.
10. Yonova D. Pruritus in certain internal diseases. Hippokratia.
2007;11(2):67–71.
11. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating
the probability of adverse drug reactions. Clin Pharmacol Ther.
1981;30(2):239–45.
12. Kitamura Y, Nakagawa H, Fujii T, et al. Effects of antihistamine
on up-regulation of histamine H1 receptor mRNA in the nasal
mucosa of patients with pollinosis induced by controlled cedar
pollen challenge in an environmental exposure unit. J Pharmacol
Sci. 2015;129(3):183–7.
13. Mizuguchi H, Orimoto N, Kadota T, et al. Suplatast tosilate
alleviates nasal symptoms through the suppression of nuclear
factor of activated T-cells-mediated IL-9 gene expression in
toluene-2,4-diisocyanate-sensitized rats. J Pharmacol Sci.
2016;130(3):151–8.
14. GIP database. Drug information system of the Dutch Health Care
Insurance Board. Available from: http://www.gipdatabank.nl.
Accessed 21 Nov 2016.
16 Page 4 of 4 C. Ekhart et al.
